Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

U

University of Colorado, Denver

Other

30

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

63

Indications↗

Distinct diseases across all programs

583

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

30 drugs in development

Approved4

Phase 32

Phase 216

Phase 18

Preclinical7

By Therapeutic Area

top 6

Oncology

919%

Metabolic & Endocrine

48%

Respiratory

36%

Cardiovascular

36%

Dermatology

24%

Neurology

12%

R&D Momentum

93/100

Pipeline Velocity

67/100

Trial Completion Rate

77/100

Pipeline Concentration

21/100

Pipeline Freshness

67/100

Strategic Signals

↗Active in Neurology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Active, not recruiting

Drug Disposition and Nephrotoxicity

Effects of Full-spectrum Cannabidiol on Alcohol Consumption and Alcohol Use Disorder Phenotypes: Implications for Precision Medicine

A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults

Active, not recruiting

Effect of Hormones on Frequency of Headache and Brain Structure and Function in Puberty

Examining the Efficacy of the Man Therapy Platform in Reducing Problematic Anger Among Military Service Members With and Without a TBI History: A Randomized Controlled Trial

Active, not recruiting

Optimizing Care in Critically Ill at UCHealth by Liberalizing the Target O2 in Mechanically-ventilated ICU Patients

Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information in Women

Biphasic Effects of Acute Alcohol Intoxication on Bystander Intervention for Sexual Violence

Werewolf Flow 50 During ACL Reconstruction: A Randomized Control Trial

Active, not recruiting

Reducing Asthma Attacks in Disadvantaged School Children With Asthma

Phase I/II Dose Escalation and Preliminary Efficacy of CD19 Directed CAR-T Cells Generated Using the Miltenyi CliniMACs Prodigy System (UCD19 CAR-T) in Pediatric Patients With Relapsed and/or Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL)

Active, not recruiting

Implementation of ThriveCircles for Clinician and Scientist Well-Being at CU SOM

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(3 drugs)

1

1

1

—

—

Cardiovascular(3 drugs)

Dermatology(2 drugs)

1

—

—

—

1

Dermatology(2 drugs)

Immunology(1 drug)

—

—

—

—

1

Immunology(1 drug)

Infectious Disease(1 drug)

—

—

1

—

—

Infectious Disease(1 drug)

Metabolic & Endocrine(4 drugs)

1

1

1

—

1

Metabolic & Endocrine(4 drugs)

Musculoskeletal(1 drug)

—

—

—

—

1

Musculoskeletal(1 drug)

Nephrology(1 drug)

—

—

1

—

—

Nephrology(1 drug)

Neurology(1 drug)

—

—

—

—

1

Neurology(1 drug)

Oncology(9 drugs)

1

4

3

—

1

Oncology(9 drugs)

Ophthalmology(1 drug)

—

—

—

—

1

Ophthalmology(1 drug)

Psychiatry(1 drug)

—

—

1

—

—

Psychiatry(1 drug)

Rare Disease(1 drug)

1

—

—

—

—

Rare Disease(1 drug)

Respiratory(3 drugs)

1

—

1

1

1

Respiratory(3 drugs)

Unknown / Other(19 drugs)

6

3

8

1

4

Unknown / Other(19 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)